Search | IOVS | ARVO Journals

Showing 1 – 20 of 80

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Persistent Retinal Detachment in Retinoblastoma: The Challenges

Sophia El Hamichi; Dhariana Acon; Veronica Kon Graversen; Aaron S Gold; Audina M Berrocal; Timothy G Murray

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2811. doi:

ARVO Annual Meeting Abstract June 2015

Retinal Detachment in a Pediatric Population: A Retrospective Review of Etiology and Outcome

Sarah Read; Hassan A Aziz; Ryan Young; Timothy G Murray; Harry W Flynn; Audina M Berrocal

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3516. doi:

Retina June 2015

Clinical and Echographic Features of Retinochoroidal and Optic Nerve Colobomas

PDF

Vincent D. Venincasa; Yasha S. Modi; Hassan A. Aziz; Bernadette Ayres; Claus Zehetner; Wei Shi; Timothy G. Murray; Harry W. Flynn, Jr; Audina M. Berrocal
TAGS: coloboma, retinal detachment, optic nerve
Invest. Ophthalmol. Vis. Sci.. 2015; 56(6):3615-3620. doi: https://doi.org/10.1167/iovs.15-16596

ARVO Annual Meeting Abstract April 2014

Successful management of ocular juvenile xanthogranuloma using off-label bevacizumab: a report of 2 cases

Noy Ashkenazy; Christopher M Henry; Ashkan M. Abbey; Craig A McKeown; Audina M Berrocal; Timothy G Murray

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5428. doi:

ARVO Annual Meeting Abstract April 2014

Evaluating surgical efficiency in the transition from the Accurus to the Constellation Vision System for microincisional vitrectomy surgery (MIVS) from an operations management perspective

Daniel Gologorsky; Timothy G Murray

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5583. doi:

ARVO Annual Meeting Abstract April 2014

Intravitreal Bevacizumab for the Treatment of Pediatric Retinal and Choroidal Diseases: Extended Follow Up

Christopher R. Henry; Robert Sisk; Jonathan Tzu; Thomas Arno Albini; Timothy G Murray; Audina M Berrocal

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5911. doi:

ARVO Annual Meeting Abstract March 2012

Endophthalmitis After Intravitreal Vascular Endothelial Growth Factor Antagonists: A Seven-year Experience At A University Referral Center.endophthalmitis After Intravitreal Vascular Endothelial Growth Factor Antagonists: A Seven-year Experience At A University Referral Center

Andrew A. Moshfeghi; Philip J. Rosenfeld; Harry W. Flynn, Jr.; Stephen G. Schwartz; Janet L. Davis; Timothy G. Murray; William E. Smiddy; Audina M. Berrocal; Thomas A. Albini

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1693. doi:

ARVO Annual Meeting Abstract March 2012

2-deoxy-D-glucose (2-DG): In vivo Evaluation of Anti-angiogenic Impact on Retinoblastoma Tumor Vasculature

Nikesh N. Shah; Samuel Houston; Yolanda Piña; Timothy G. Murray; Christina L. Decatur; Jaime Merchan; Theodore Lampidis

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1873. doi:

ARVO Annual Meeting Abstract March 2012

Use of AMP-kinase Activator 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) in the Treatment of Retinoblastoma

Christina L. Decatur; Nikesh Shah; Yolanda Piña; Marcela Lonngi; Dien Pham; Samuel Houston; Timothy G. Murray

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1875. doi:

ARVO Annual Meeting Abstract March 2012

Evaluation of Learning Curve for 125-Iodine Plaque Brachytherapy Placement: A 19 Year Review

Milena L. Cavalcante; Nisha V. Shah; Steven K. Houston, III; Timothy G. Murray; Arnold M. Markoe

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3406. doi:

ARVO Annual Meeting Abstract March 2012

Combined Microincisional Vitrectomy and Phacoemulsification in the Management of Complications Associated with 125-I Brachytherapy Treated Patients with Uveal Malignant Melanoma

Marcela Lonngi; Timothy G. Murray; Robert A. Sisk; David W. Parke, III; Audina M. Berrocal; Samuel K. Houston

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3410. doi:

ARVO Annual Meeting Abstract March 2012

Effect of Early SD-OCT Diagnosis Followed by Prompt Treatment of Radiation Retinopathy with anti-VEGF Agents on Visual Acuity

Nisha V. Shah; Samuel K. Houston; William J. Feuer; Timothy G. Murray

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3424. doi:

ARVO Annual Meeting Abstract March 2012

Intravitreal Bevacizumab As An Adjuvant Agent To Plaque Brachytherapy Reduces Tumor Burden And Enhances The Resolution Of Exudative Detachment

Samuel K. Houston; Nisha Shah; Christina L. Decatur; Marcela Lonngi; William J. Feuer; Timothy G. Murray

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3425. doi:

Anatomy and Pathology/Oncology February 2012

Retinoblastoma Treatment: Utilization of the Glycolytic Inhibitor, 2-deoxy-2-fluoro- d -glucose (2-FG), to Target the Chemoresistant Hypoxic Regions in LH BETA T AG Retinal Tumors

PDF

Yolanda Piña; Christina Decatur; Timothy G. Murray; Samuel K. Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
TAGS: glucose, hypoxia, neoplasms, retinal neoplasms, retinoblastoma
Invest. Ophthalmol. Vis. Sci.. 2012; 53(2):996-1002. doi: https://doi.org/10.1167/iovs.11-8265

Genetics July 2011

Regional and Temporal Differences in Gene Expression of LH BETA T AG Retinoblastoma Tumors

PDF

Samuel K. Houston; Yolanda Pina; Jennifer Clarke; Tulay Koru-Sengul; William K. Scott; Lubov Nathanson; Amy C. Schefler; Timothy G. Murray
TAGS: gene expression, neoplasms, retinoblastoma
Invest. Ophthalmol. Vis. Sci.. 2011; 52(8):5359-5368. doi: https://doi.org/10.1167/iovs.10-6321

ARVO Annual Meeting Abstract April 2011

Correlation of Baseline Echographic Features with Visual Acuity and Microbiological Culture Outcomes in Patients with Clinically Diagnosed Endophthalmitis

Aleksandra Rachitskaya; Harry W. Flynn, Jr.; Fiona Ehlies; Maria B. Ayres; Timothy G. Murray

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5604. doi:

ARVO Annual Meeting Abstract April 2011

Clinical Features and Outcomes of Same-Day versus Delayed Pars Plana Vitrectomy for Retained Lens Fragments

Justin H. Townsend; Lisa C. Olmos; Harry W. Flynn, Jr.; William E. Smiddy; Timothy G. Murray

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6112. doi:

ARVO Annual Meeting Abstract April 2011

A Novel, Oral, Non-invasive Method Of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose In The Treatment Of Retinoblastoma

Timothy G. Murray; Christina Decatur; Yolanda Piña; Samuel Houston; Ludimilla Cavalcante; Theodore Lampidis

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1592. doi:

ARVO Annual Meeting Abstract April 2011

Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors

Samuel K. Houston; Timothy G. Murray; Christina L. Decatur; Yolanda Pina; Ludimila Cavalcante; Theodore Lampidis

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2487. doi:

ARVO Annual Meeting Abstract April 2011

Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists: A Six-Year Experience at a University Referral Center

Harry W. Flynn, Jr.; Andrew A. Moshfeghi; Philip J. Rosenfeld; Stephen G. Schwartz; Timothy G. Murray; William E. Smiddy; Audina M. Berrocal; Sander R. Dubovy, Jr.; Wen-Hsiang Lee; Thomas A. Albini

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5926. doi:

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Persistent Retinal Detachment in Retinoblastoma: The Challenges

Retinal Detachment in a Pediatric Population: A Retrospective Review of Etiology and Outcome

Clinical and Echographic Features of Retinochoroidal and Optic Nerve Colobomas

Successful management of ocular juvenile xanthogranuloma using off-label bevacizumab: a report of 2 cases

Evaluating surgical efficiency in the transition from the Accurus to the Constellation Vision System for microincisional vitrectomy surgery (MIVS) from an operations management perspective

Intravitreal Bevacizumab for the Treatment of Pediatric Retinal and Choroidal Diseases: Extended Follow Up

Endophthalmitis After Intravitreal Vascular Endothelial Growth Factor Antagonists: A Seven-year Experience At A University Referral Center.endophthalmitis After Intravitreal Vascular Endothelial Growth Factor Antagonists: A Seven-year Experience At A University Referral Center

2-deoxy-D-glucose (2-DG): In vivo Evaluation of Anti-angiogenic Impact on Retinoblastoma Tumor Vasculature

Use of AMP-kinase Activator 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) in the Treatment of Retinoblastoma

Evaluation of Learning Curve for 125-Iodine Plaque Brachytherapy Placement: A 19 Year Review

Combined Microincisional Vitrectomy and Phacoemulsification in the Management of Complications Associated with 125-I Brachytherapy Treated Patients with Uveal Malignant Melanoma

Effect of Early SD-OCT Diagnosis Followed by Prompt Treatment of Radiation Retinopathy with anti-VEGF Agents on Visual Acuity

Intravitreal Bevacizumab As An Adjuvant Agent To Plaque Brachytherapy Reduces Tumor Burden And Enhances The Resolution Of Exudative Detachment

Retinoblastoma Treatment: Utilization of the Glycolytic Inhibitor, 2-deoxy-2-fluoro- d -glucose (2-FG), to Target the Chemoresistant Hypoxic Regions in LH BETA T AG Retinal Tumors

Regional and Temporal Differences in Gene Expression of LH BETA T AG Retinoblastoma Tumors

Correlation of Baseline Echographic Features with Visual Acuity and Microbiological Culture Outcomes in Patients with Clinically Diagnosed Endophthalmitis

Clinical Features and Outcomes of Same-Day versus Delayed Pars Plana Vitrectomy for Retained Lens Fragments

A Novel, Oral, Non-invasive Method Of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose In The Treatment Of Retinoblastoma

Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors

Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists: A Six-Year Experience at a University Referral Center

To View More...

You must be signed into an individual account to use this feature.